Moreover, comparative genomic analysis of cfDNA from 1122 EGFRM+ and 1008 EGFR-wt patients with stage III/IV NSCLC illustrated the extensive co-occurrence of other crucial somatic genetic alterations in the EGFRM+ population before TKI-therapy [12]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.